Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs

CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.

Back view image of young businessman standing against business sketch
Analysts wonder if Intercept is de-emphasizing NASH to focus on PBC

Market analysts have been trying to read the tea leaves regarding Intercept Pharmaceuticals, Inc.’s prospects for getting obeticholic acid (OCA) refiled for US approval in non-alcoholic steatohepatitis for months now, and while the firm’s fourth quarter/full-year 2020 earnings call on 25 February offered assurances about refiling the new drug application by year’s end, those same analysts don’t seem fully convinced.

[Sidebar#SC143285]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.